Our Insights Oncology Anthony Iannacci 7/21/20 Oncology Anthony Iannacci 7/21/20 Pfizer Combo Gains an Edge in BRAF+ Melanoma Read More Oncology Anthony Iannacci 6/2/20 Oncology Anthony Iannacci 6/2/20 A Reliable Predictor of NICE Recommendation Read More Oncology Anthony Iannacci 5/27/20 Oncology Anthony Iannacci 5/27/20 Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma Read More Oncology Anthony Iannacci 5/4/20 Oncology Anthony Iannacci 5/4/20 Lynparza: Expanding into Prostate Cancer Read More Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More Oncology Anthony Iannacci 3/26/20 Oncology Anthony Iannacci 3/26/20 Enhertu: A New Leader in Later-Line Breast Cancer Read More Oncology Anthony Iannacci 1/29/20 Oncology Anthony Iannacci 1/29/20 PARP Inhibitors: Promise in New Maintenance Indications Read More Oncology Anthony Iannacci 12/16/19 Oncology Anthony Iannacci 12/16/19 Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model Read More Oncology Anthony Iannacci 10/22/19 Oncology Anthony Iannacci 10/22/19 Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC Read More Oncology Anthony Iannacci 6/18/19 Oncology Anthony Iannacci 6/18/19 Calquence: The price is right Read More Oncology, R&D Insights Anthony Iannacci 6/5/19 Oncology, R&D Insights Anthony Iannacci 6/5/19 How to Price an Oncology Drug Read More Oncology Anthony Iannacci 4/8/16 Oncology Anthony Iannacci 4/8/16 Imbruvica: Closing the window of opportunity in CLL Read More Oncology Anthony Iannacci 11/10/15 Oncology Anthony Iannacci 11/10/15 Keytruda: Exceptional early results in a small colorectal cancer population Read More Oncology Anthony Iannacci 10/31/15 Oncology Anthony Iannacci 10/31/15 Blincyto: High price for an undifferentiated drug Read More Oncology Anthony Iannacci 10/15/15 Oncology Anthony Iannacci 10/15/15 PD-1 Inhibitors: Strong starts in three indications Read More Oncology Anthony Iannacci 9/16/15 Oncology Anthony Iannacci 9/16/15 Avastin: One molecule in multiple cancers Read More Oncology Anthony Iannacci 8/14/15 Oncology Anthony Iannacci 8/14/15 Kyprolis: A rapid rise in a crowded market Read More Newer Posts Want to get in touch? Click here
Oncology Anthony Iannacci 7/21/20 Oncology Anthony Iannacci 7/21/20 Pfizer Combo Gains an Edge in BRAF+ Melanoma Read More
Oncology Anthony Iannacci 6/2/20 Oncology Anthony Iannacci 6/2/20 A Reliable Predictor of NICE Recommendation Read More
Oncology Anthony Iannacci 5/27/20 Oncology Anthony Iannacci 5/27/20 Brukinsa: Shooting behind the duck in R/R mantle cell lymphoma Read More
Oncology Anthony Iannacci 5/4/20 Oncology Anthony Iannacci 5/4/20 Lynparza: Expanding into Prostate Cancer Read More
Oncology, R&D Insights Anthony Iannacci 4/2/20 Oncology, R&D Insights Anthony Iannacci 4/2/20 Finding the Right Price for a Drug across Multiple Indications; Learnings from Keytruda Read More
Oncology Anthony Iannacci 3/26/20 Oncology Anthony Iannacci 3/26/20 Enhertu: A New Leader in Later-Line Breast Cancer Read More
Oncology Anthony Iannacci 1/29/20 Oncology Anthony Iannacci 1/29/20 PARP Inhibitors: Promise in New Maintenance Indications Read More
Oncology Anthony Iannacci 12/16/19 Oncology Anthony Iannacci 12/16/19 Candidate Observations to Be Added to Equinox’s Oncology Normative Pricing Model Read More
Oncology Anthony Iannacci 10/22/19 Oncology Anthony Iannacci 10/22/19 Tecentriq and Imfinzi Both Offer Modest Improvements in SCLC Read More
Oncology Anthony Iannacci 6/18/19 Oncology Anthony Iannacci 6/18/19 Calquence: The price is right Read More
Oncology, R&D Insights Anthony Iannacci 6/5/19 Oncology, R&D Insights Anthony Iannacci 6/5/19 How to Price an Oncology Drug Read More
Oncology Anthony Iannacci 4/8/16 Oncology Anthony Iannacci 4/8/16 Imbruvica: Closing the window of opportunity in CLL Read More
Oncology Anthony Iannacci 11/10/15 Oncology Anthony Iannacci 11/10/15 Keytruda: Exceptional early results in a small colorectal cancer population Read More
Oncology Anthony Iannacci 10/31/15 Oncology Anthony Iannacci 10/31/15 Blincyto: High price for an undifferentiated drug Read More
Oncology Anthony Iannacci 10/15/15 Oncology Anthony Iannacci 10/15/15 PD-1 Inhibitors: Strong starts in three indications Read More
Oncology Anthony Iannacci 9/16/15 Oncology Anthony Iannacci 9/16/15 Avastin: One molecule in multiple cancers Read More
Oncology Anthony Iannacci 8/14/15 Oncology Anthony Iannacci 8/14/15 Kyprolis: A rapid rise in a crowded market Read More
